Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

Bavarian Nordic’s smallpox vaccine is approved for use against monkeypox by the U.S. Food and Drug Administration and Health Canada.

Bavarian Nordic A/S announced today the signing of a number of supply contracts with undisclosed countries for the company’s smallpox vaccine with the aim to ensure sufficient supply to meet the requirements for vaccinating individuals at risk for monkeypox in the short to medium term.

While the terms of the agreements remain undisclosed. Bavarian Nordic is currently in dialogue with additional countries concerning supply of the vaccine to mitigate the current monkeypox outbreak and to explore opportunities for longer term collaboration to build stockpiles for future preparedness.

The company said it was making every possible effort to ensure sufficient availability of vaccines to meet the current demand in this unprecedented situation.